Antiviral Drugs Market Size & Share, by Drug Class - (DNA Polymerase, Reverse Transcription, Protease, Neuraminidase Inhibitors); Indication - (Influenza, HIV, AIDS, Hepatitis, Harper Simplex Virus (HSV), Coronavirus Infection); Type - (Branded, Generic); Age Group - (Pediatric, Adult, Geriatric) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2033

  • Report ID: 473
  • Published Date: Feb 13, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023-2033

Antiviral Drugs Market size is anticipated to reach USD 70 Billion by the end of 2033, growing at a CAGR of 4% during the forecast period, i.e., 2023-2033. In the year 2022, the industry size of antiviral drugs was over USD 52 Billion.The increasing cases of hepatitis B infection and high investment in R&D activities on antiviral drugs across the world are estimated to propel the market growth during the forecast period. As per the World Health Organization, about 296 million people are suffered from chronic hepatitis B infection in 2019.

The growing incidence rate of infectious diseases such as herpes simplex virus, hepatitis virus, and influenza. As per the observations, between September to October 2022, nearly 5300 members tested positive for the influenza virus.


Antiviral Drugs Market
Get more information on this report: Request Free Sample PDF

Antiviral Drugs Sector: Growth Drivers and Challenges

Growth Drivers

  • Rising Geriatric Population – The rising number of old people across the world and their rising high chances of getting viral infections is estimated to boost the antiviral drugs market growth during the forecast period. Old people are susceptible to diseases due to less immune strength which makes them more prone to any disease or infection. As per the World Health Organization, the number of people aged 60 years and above rose from 1 billion in 2020 to 1.4 billion in 2022.
  • Increased Cases of COVID – 19 – The number of global COVID cases across the world in 2022 was 625,700,400 as per the estimations.
  • Rising Risk of STDs Among Adults – According to the observations, over 1 million sexually transmitted diseases occur each year with an estimated more than 350 new infections.
  • Growing Demand for Generic Versions – As per the IMS Health Institute, the healthcare system of the U.S saved USD 2.2 trillion between 2009 to 2019 with the use of generic drugs.
  • Rising Vaccinations Against Viral Infections – The COVID-19 vaccine was administered in more than 13 billion doses until 2022.

Challenges

  • Increasing Awareness About Preventive Drugs Treatment
  • Presence of Generics
  • Drug Resistance

Antiviral Drugs Market: Key Insights

Base Year

2022

Forecast Year

2023-2033

CAGR

~4%

Base Year Market Size (2022)

 ~ USD 52 Billion

Forecast Year Market Size (2033)

~ USD 70 Billion

Get more information on this report: Request Free Sample PDF

Antiviral Drugs Segmentation

Drug Class - (DNA Polymerase, Reverse Transcription, Protease, Neuraminidase Inhibitors)

The global antiviral drugs market is segmented and analyzed for demand and supply by drug class into DNA polymerasesreverse transcription, protease, and neuraminidase inhibitors. Out of these, reverse transcription is anticipated to hold the largest market size by the end of 2033 on the back of the growing diagnosis and treatment rate of HIV infection and the increasing efficiency of antiviral drugs on viral diseases. In 2021, about 29 million individuals who suffered from HIV received antiretroviral therapy.

Major Macro-Economic Indicators Impacting the Market Growth

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5,355.79, which grew from USD 3,515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in the upcoming years.

Our in-depth analysis of the global market includes the following segments:

 

               By Drug Class

  • DNA Polymerase Inhibitors
  • Reverse Transcription Inhibitors
  • Protease Inhibitors
  • Neuraminidase Inhibitors

 

 

             By Indication

  • Influenza
  • HIV
  • AIDS
  • Hepatitis
  • Herpes Simplex Virus (HSV)
  • Coronavirus Infection

             By Type

  • Branded
  • Generic

 

             By Age Group

  • Pediatric
  • Adult
  • Geriatric

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Antiviral Drugs Industry - Regional Synopsis

Regionally, the global antiviral drugs market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. Amongst these markets, the market in North America region is projected to hold the largest market share by the end of 2033 on the back of a growing patient base, the strong foothold of industry key players, increasing approval, and the expected commercialization of new drugs for viral diseases.  In 2022, the number of COVID-19 cases increased by 8% in North America.

Research Nester
Antiviral Drugs Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Antiviral Drugs Landscape

top-features-companies
    • AstraZeneca LP
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline, Plc
    • Bristol Myers Squibb Company
    • Abbott Laboratories
    • Plough Publishing House
    • Merck & Co., Inc
    • Johnson & Johnson Services, Inc
    • AbbVie Inc.
    • Cipla Inc.
    • Dr Reddy’s Laboratories Ltd.

In the News

  • Merck & Co., Inc. announced that Molnupiravir, an oral antiviral investigational medicine used to reduce the risk of hospitalization or death.

  •  Johnson & Johnson Services, Inc. declared the introduction of a multi-pronged response against novel Coronavirus. This is also used to determine the coronavirus pathophysiology to help patients survive from 2019-nCoV infection.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 473
  • Published Date: Feb 13, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising cases of HIV, AIDS, Hepatitis, and STDs among adults are the major factors driving the growth of the antiviral drugs market.

The market is anticipated to attain a CAGR of ~4% over the forecast period, i.e., 2023-2033.

Rising awareness about preventive drug treatment and drug resistance are the challenges affecting the market growth.

The market in North America region is projected to hold the largest market share by the end of 2033 and provide more business opportunities in the future.

The major players in the market are F. Hoffmann-La Roche Ltd, GlaxoSmithKline, Plc, Bristol Myers Squibb Company, Abbott Laboratories, Plough Publishing House, Merck & Co., Inc, Johnson & Johnson Services, Inc, AbbVie Inc., Cipla Inc., Dr Reddy’s Laboratories Ltd.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue-generating capacity as well as the new products being launched into the market by the company.

The market is segmented by drug class, indication, type, age group, and by region.

The reverse transcriptase segment is anticipated to garner the largest market size by the end of 2033 and display significant growth opportunities.
Antiviral Drugs Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying